{"id":824296,"date":"2025-03-11T09:06:51","date_gmt":"2025-03-11T13:06:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/"},"modified":"2025-03-11T09:06:51","modified_gmt":"2025-03-11T13:06:51","slug":"neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/","title":{"rendered":"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain"},"content":{"rendered":"
\n

\n Submission for New Intended Use That Leverages Company\u2019s Patented OneRF\u00ae Technology Platform Expected in May 2025\u00a0<\/em>\n <\/p>\n

\n EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) — <\/strong>NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company\u2019s patented OneRF\u00ae<\/sup> Technology Platform. The Company had previously projected a submission by the end of June 2025.<\/p>\n

Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face caused by trigeminal neuralgia. The trigeminal nerve is the main sensory nerve in the face and NeuroOne\u2019s procedure is designed to provide pain relief for this condition. According to the October 2024 Research and Markets report titled Trigeminal Neuralgia Therapeutics Market, the trigeminal neuralgia therapeutics market, comprised of pharmacologic and surgical technologies, is expected to grow from $262 million in 2024 to over $416 million by 2030, primarily due to an aging population.<\/p>\n

\u201cBuilding on the success of our three product families that have already achieved 510(k) FDA clearance, we have accelerated our submission timeline for the OneRF Trigeminal Nerve Ablation System, approximately two months ahead of schedule,\u201d said Dave Rosa, President and Chief Executive Officer of NeuroOne. \u201cIf cleared by the FDA\u2014we believe there is a potential to generate revenues from trigeminal nerve ablation in late 2025, which was not previously expected in calendar year 2025.<\/p>\n

\u201cImportantly, trigeminal nerve ablation would be the second radiofrequency ablation technology in our portfolio leveraging our patented OneRF\u00ae<\/sup> Technology Platform. As we move ahead, we believe there are several additional ablation applications we can introduce and look forward to updating you on our progress as we move throughout the year.\u201d<\/p>\n

\n About NeuroOne<\/strong>\n <\/p>\n

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson\u2019s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit\u00a0nmtc1.com<\/a>.<\/u><\/p>\n

\n Forward Looking Statements<\/strong>\n <\/p>\n

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward\u2013looking statement that reflects NeuroOne\u2019s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward\u2013looking statements by the words or phrases \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cforecasts,\u201d \u201cobjective,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ctarget,\u201d \u201cseek,\u201d \u201ccontemplate,\u201d \u201ccontinue, \u201cfocused on,\u201d \u201ccommitted to\u201d and \u201congoing,\u201d or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward\u2013looking statements may include statements regarding the plan to submit a 510(k) application with the FDA in May 2025 for our trigeminal nerve ablation program, the potential to receive revenue from the commercialization of our trigeminal nerve ablation program in 2025 or at all, our business strategy, market size, potential growth opportunities, future operations, future efficiencies, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations for the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology\u037e whether due to supply chain disruptions, labor shortages or otherwise\u037e risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials\u037e risks related to uncertainties associated with the Company\u2019s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology\u037e uncertainties inherent in the development process of our technology\u037e risks related to changes in regulatory requirements or decisions of regulatory authorities\u037e that we may not have accurately estimated the size and growth potential of the markets for our technology\u037e risks relate to clinical trial patient enrollment and the results of clinical trials\u037e that we may be unable to protect our intellectual property rights\u037e and other risks, uncertainties and assumptions, including those described under the heading \u201cRisk Factors\u201d in our filings with the Securities and Exchange Commission. These forward\u2013looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward\u2013looking statements for any reason, even if new information becomes available in the future.<\/p>\n

Caution: Federal law restricts this device to sale by or on the order of a physician.<\/p>\n

\n IR Contact<\/strong>
\n
MZ Group \u2013 MZ North America
NMTC@mzgroup.us<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Submission for New Intended Use That Leverages Company\u2019s Patented OneRF\u00ae Technology Platform Expected in May 2025\u00a0 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company\u2019s patented OneRF\u00ae Technology Platform. The Company had previously projected a submission by the end of June 2025. Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face caused … <\/p>\n

Continue reading “NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-824296","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nNeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Submission for New Intended Use That Leverages Company\u2019s Patented OneRF\u00ae Technology Platform Expected in May 2025\u00a0 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company\u2019s patented OneRF\u00ae Technology Platform. The Company had previously projected a submission by the end of June 2025. Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face caused … Continue reading "NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-11T13:06:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain\",\"datePublished\":\"2025-03-11T13:06:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/\"},\"wordCount\":948,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/\",\"name\":\"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==\",\"datePublished\":\"2025-03-11T13:06:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/","og_locale":"en_US","og_type":"article","og_title":"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain - Market Newsdesk","og_description":"Submission for New Intended Use That Leverages Company\u2019s Patented OneRF\u00ae Technology Platform Expected in May 2025\u00a0 EDEN PRAIRIE, Minn., March 11, 2025 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has accelerated the anticipated timeline of its 510(k) submission to the FDA for trigeminal nerve ablation to May 2025, which leverages the Company\u2019s patented OneRF\u00ae Technology Platform. The Company had previously projected a submission by the end of June 2025. Trigeminal nerve ablation is a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue to relieve severe, chronic pain in the face caused … Continue reading \"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-11T13:06:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain","datePublished":"2025-03-11T13:06:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/"},"wordCount":948,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/","name":"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==","datePublished":"2025-03-11T13:06:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM5MjAwMyM2Nzk5MzA3IzUwMDExNDgzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-accelerates-timeline-of-510k-submission-to-fda-for-the-onerf-trigeminal-nerve-ablation-system-to-treat-facial-pain\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NeuroOne\u00ae Accelerates Timeline of 510(k) Submission to FDA for the OneRF\u00ae Trigeminal Nerve Ablation System to Treat Facial Pain"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/824296","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=824296"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/824296\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=824296"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=824296"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=824296"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}